Shruti Bhat PhD, MBA, Operations Excellence Expert
  • Home
  • About Shruti
  • Books
  • Insights
  • Operational Excellence
  • Research
    • Innovation Management
    • Leading Research and Development
    • Developer's Diary
  • Case Studies
  • Tools
    • Whitepapers
    • Articles >
      • Business Transformation
      • Process Improvement
      • Business Continuity
      • Change Management
      • Digital Transformation
      • Quality Improvement
    • Checklists and Templates
    • Free eBook
    • Videos
  • Blog
  • Engage Shruti
    • Consulting >
      • Operational Excellence Consulting
      • Business Transformation Consulting
      • Innovation Management Consulting
    • Workshops
  • Contact

DRUG UPDATES

12/22/2009

0 Comments

 
FDA approves expanded indication for Spiriva HandiHaler.
"Spiriva HandiHaler [inhaled tiotropium bromide]" has been approved by the US Food and Drug Administration "as a treatment for reducing symptoms and difficulty breathing because of chronic obstructive pulmonary disease (COPD)."  

The new indication was based on results of two clinical trials with nearly 8,000 patients combined -- one called UPLIFT and a separate six-month study with patients in a Veterans Affairs setting. Although the UPLIFT study did not achieve its primary endpoint of showing a slowed rate of lung function decline relative to placebo, clinical data demonstrated that the addition of tiotropium to preexisting respiratory medications sustained improved lung function during four years and reduced COPD exacerbations.

EU drug regulators recommend approval of Prolia.
Sources from  Amgen Inc. said  that the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of the biotechnology company's osteoporosis drug Prolia, also called denosumab." The drug is still under FDA review "as a potential treatment for postmenopausal osteoporosis and as a treatment for bone loss in breast and prostate cancer patients undergoing therapy."

Researchers investigating whether oral enzymes, immunotherapy effective in celiac disease. Many efforts underway to develop new, non-dietary treatments for celiac disease," including "a gluten-free diet" and protecting "patients from occasional gluten exposure" using "oral enzymes that target gluten." Researchers have found that when gluten is "broken down into smaller fragments" by combining "enzymes from bacteria and barley," it "no longer causes inflammation in the intestines." Meanwhile, researchers are also investigating whether training "the immune system to tolerate gluten" and allowing "patients to eat a regular diet" is effective. This "category of treatment, known as immunotherapy," quells "immune response in the gut," which "is driven by...cells known as T cells."

Sanofi stops tests on drugs for insomnia, atrial fibrillation.
Sanofi-Aventis SA reportedly stopped tests on two medicines for insomnia and atrial fibrillation because of setbacks in development." The drug-maker "withdrew applications in Europe and the US for the insomnia pill eplivanserin because of the need for 'significant further clinical development and market access constraints,' the Paris-based company said." Meanwhile, according to Sanofi, "the idrabiotaparinux medicine for use in preventing clots in patients with atrial fibrillation is being discontinued because of 'recent therapeutic advances in the field.'

Celgene says Revlimid slowed multiple myeloma progression.
Celgene Corp. Correspondent stated that  data from a late-stage study show Revlimid [lenalidomide] significantly slowed the progression of multiple myeloma in patients following a type of stem cell treatment." The study included patients "who...received autologous stem cell transplants, a procedure where stem cells are removed from a person's bone marrow prior to chemotherapy, then reintroduced after chemotherapy." The drug is currently "approved as treatment for multiple myeloma patients who have received at least one prior therapy."

Follow Shruti on Twitter, Facebook, YouTube, LinkedIn
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Shruti Bhat, global leader in business turnaround, operational excellence and continuous improvement
    To contact Dr. Shruti Bhat text or WhatsApp at 1.403.969.6219

    New Book Released!

    Revolutionizing Industries with Lean Six Sigma

    Shruti's YouTube Channel ...

    Picture

    Blog Categories

    All
    3D Printing
    Agile
    Artificial Intelligence
    Automation
    Biotechnology
    Books
    Business Continuity
    Business Turnaround
    Case Studies
    Change Management
    Checklists
    Chemical Industry
    Continuous Improvement
    Design Thinking
    Digitalization
    Drug Delivery
    External News Links
    Hall Of Fame
    Healthcare
    Hoshin Kanri
    HR Development
    Innovation
    Insights
    ISO
    Just In Time
    Kaizen
    Leadership
    LEAN
    Lean Six Sigma
    Life Sciences
    Machine Learning
    Manufacturing
    Medical Devices
    Mistake Proofing
    Motivational Cards
    MSMEs
    Nanotechnology
    Operational Excellence
    Packaging
    Patents
    Personal Products
    Process Improvement
    Product Development
    Productivity Increase
    QbD
    Quality Management
    R&D Leadership
    Robotics
    Service Industry
    Six Sigma
    Strategy
    Supply Chain Logistics
    Telecom Industry
    Templates
    TQM
    Videos
    Voice Of Customer
    Whitepaper
    Workshops

    Shruti's books...

    Picture
    top ten strategic decision-making tools for operational excellence
    shruti bhat, business process management, continuous improvement
    kaizen for pharmaceutcials, medical devices and biotech industry book by Dr Shruti Bhat
    Book on Continuous improvement tools by Dr Shruti Bhat
    kaizen for leaders, continuous process improvement tool to increase profit and organizational excellence by shruti bhat
    kaizen, shruti bhat, continuous improvement, quality, operations management
    how to lead a successful business transformation
    leading organizations through crisis
    emotional intelligence
    how to overcome challenges of creating effective teams
    modular kaizen Vs Blitz kaizen
    How to increase employee engagement as a new boss

Connect with Dr. Shruti Bhat at- ​Twitter, YouTube, LinkedIn​

© Copyright 1992- 2025 Dr. Shruti Bhat ALL RIGHTS RESERVED.
See Terms and Conditions for details on this site usage.
Subscribe to Operational Excellence Academy YouTube Channel
​Subscribe to Operational Excellence Academy YouTube Channel
SHRUTI BHAT, CONTACT
Click to connect.
Created by Macro2Micro Media